Moderna has updated its October 2020 pledge not to enforce patents on its COVID-19 vaccine for manufacturers that supply vaccines to or in 92 low- and middle-income countries during the pandemic.

Moderna added that it will never enforce the patents provided that the vaccines are solely for use in those countries.

Elsewhere in the world, the company said it remains willing to license its technology for COVID-19 vaccines to manufacturers “on commercially reasonable terms.”

Moderna said the licensing decision was made in order to continue to invest in research to develop new vaccines and to meet “pressing areas of unmet medical need.”

Moderna earned $17.7 billion in sales of its COVID-19 vaccine Spikevax in 2021.